Our clinical protocol included radionuclide voiding cystography (RNC) at postoperative 3 months, 1 year and 3 years to assess the VUR resolution.
Introduction
Vesicoureteral reflux (VUR) is known to occur in 1% of children and is one of the major causes of urinary tract infection (UTI) and chronic renal failure 1, 2) . The purpose of diagnosing and treating VUR is to prevent these compli cations. In the past, if medical treatment represented by prophylactic low dose antibiotics failed, ureteroneocystostomy (UNC) was the only alternative. However, a subureteral injection technique has been in the limelight as a sur gical method to replace UNC after Matouscheck first reported on this tech nique using a cystoscope in 1981 and O'Donnell reported the first clinical examples in 1984 3, 4) . Teflon ® , bovine collagen, Macroplastique ® and other materials have been used as injection substances, but there are still many limitations in their efficacy and safety in the pedi atric area 57) . Since Stenberg and Läckgren reported the first clinical application of Dextranomer/hyaluronic acid (DX/HA) copolymer (Deflux ® , QMed Scandinavia, Up psala, Sweden) in 1995 8) , Deflux ® injection therapy has been recognized as an alternative treatment for VUR in the pediatric area. The overall success rate of Deflux ® in jection therapy has been reported as 6892% and is known to be affected mainly by the grade of VUR 6, 911) . Deflux ® injection therapy also has the clinical advantages of fewer complications and a shorter hospital stay. Since research on the success rate of Deflux ® injection therapy for VUR in children was first reported in Korea 12) , there have not been enough reports on its longterm prognosis, including the amount of pyelonephritis occurrence and the recur rence of VUR. Thus, this study analyzed the longterm results in children who underwent Deflux ® injection and evaluated the prognosis of Deflux ® injection therapy. power field (centrifuged specimen) or a trace or more leuko cyte esterase on a dipstick) and more than 100,000 colony forming units of bacteria per mL in a uri ne culture test of a clean urine specimen 24) . The indica tions for Def lux ® injection therapy were the following: a deteriora tion in the affected renal function due to febrile UTI; Persistence of VUR despite relatively old age; severe VUR of grade IVV; and patients whose caregivers were reluc tant to antibiotics prophylaxis. The therapy was carried out preventively when there were abnormal find ings in the ureteral orifice shape on the opposite side of the affected area in a cystoscopy conducted during surgery (3 ureters were done for this in dication). Post operatively, VUR Grade I was considered to be a suc cessful procedure (pre operative Grade I based on the suc cess rate of the ure ter was judged as a successful surgery when the postoperative grade was 0), and a con tinuous postopera tive VUR of more than Grade II or a re currence was judged as a failure. If VUR was present during the RNC test conducted after the procedure, prophylactic oral anti biotics were given, or Deflux ® injection was per formed again, or UNC were performed on patient who required definite surgical pro cedure. Voiding dysfunction is defined as urination pattern that is abnormal for the child's age. We considered child has voiding dysfunction if child has any of these symptoms; incontinence (urine leakage) during the day and/or night, increase in urinary frequency, urgency (the need to void immediately), urinary hesitancy, dribbling, intermittent urine flow, straining at urination, and/or pain in the back, flank or abdomen. Constipation is defined as defecation less than twice a week according to ROME III criteria. Trabeculation of bladder is graded by formation of muscle bundle and depth of mucosal layer on cystoscopic exam (none, mild, moderate, and severe). Cortical defect on DMSA scan is decided by nuclear radiologists and defined as single or multiple, focal or diffuse areas of decreased or completely absent activity in the renal cortex; (2) 
Materials and methods

Results
The mean age of the 243 patients included in this study was 53 (1270) months at the time of surgery; there were 137 boys and 106 girls. The followup period of pediatric urology outpatient was 32 (1113) months. Five patients complained of preoperative dysuria, such as straining or hesitancy, and 12 people complained of constipation. In a preoperative voiding cystourethrogram (VCUG), VUR was observed in 416 ureter units and the frequency of each VUR grade was 67 for grade I, 96 for grade II, 118 for grade III, 97 for grade IV and 38 for grade V. Postoperative com plica tions were observed in one case that gross hema turia oc curred after leaving the hospital, but was treated with con servative treatments such as oral fluid intake, etc. There were no cases of urinary tract infection caused by the sur gery (Table 1 ). All 243 patients under went an RNC test at postoperative 3 months, and 172 patients (70.8%) had no VUR. At postoperative 1 year, 171 patients under went an RNC test and 110 patients (64.3%) had no VUR. At post operative 3 years, 90 patients under went an RNC test and 59 patients (65.6%) had no VUR. In ureteral num bers, an RNC test was evaluated for 419 ureters at post operative 3 months and 333 ureters showed no VUR (79.5 %); at post operative 1 year, 212 ureters out of 282 ureters (75.2%) and at postoperative 3 years, 97 ureters out of 127 ureters (76.4 %) showed no VUR.
Based on VUR grade, the cure rates at postoperative 3 months were 92.5%, 84.4%, 72.9%, 75.3% and 73.7% for grade I, grade II, grade III, grade IV and grade V, respec tive ly. At postoperative 1 year, the cure rates were 84.2%, 74.3%, 81.6%, 72.4% and 48.2%, respectively, and at post operative 3 years, 81.3%, 70.6%, 81.1%, 78.6% and 63.6%, respectively. The cure rates by grade at postoperative 3 months and 1 year showed a statistically significant differ ence (P=0.015, P=0.010). Based on age, the cure rates at post operative 3 months, 1 year and 3 years were 58.1%, 51.1 % and 66.7% for 012 months; 75.5%, 50.0% and 65.0% for 1336 months; 76.2%, 75.8% and 68.8% for 3760 months; and 74.4%, 74.6% and 63.6% in more than 60 months. The cure rates by age at postoperative 1 year showed a statisti cally significant difference (P=0.012) (Fig. 1) .
Of the ureters that underwent RNC tests at both post operative 1 year and 3 years, reflux was observed in 22 ureters (55.0%) after 3 years out of 40 ureters that showed reflux in an RNC test at 1 year. In contrast, reflux was ob served in only 8 ureters (10.3%) after 3 years out of 78 ure ters that did not show reflux at 1 year and there was a statistically significant difference (P<0.001).
After the first Deflux ® injection, another Deflux ® injection was carried out for 33 patients. Among them, 5 pa tients injection therapy, such as sex, age at surgery, degree of VUR, presence or absence of voiding dysfunction, presence or absence of constipation, degree of trabeculation in the bladder, etc., age at surgery and degree of VUR were the factors that may affect the success rate at postoperative 1 year accord ing to the uni variate analysis, and in the multi variate ana lysis, it was found that no factors had a statistic ally signifi cant correlation (P>0.05). There was no statistic ally sig ni ficant factor that may affect the success rate at post operative 3 months and postoperative 3 years (Table 2) . 
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Discussion
In the treatment of VUR, the concept of subureteral in jection therapy under a cystoscope has developed conside rably since it was introduced in the 1980s 3, 4) . This treatment is thought to resolve VUR by forming solid sup port behind the intravesical ureter and increasing the submu cosal length of the ureter 3) . Many studies have reported the effi cacy and safety of endoscopic treatment as a firstline treatment for VUR 1316) . Since first reported by Sten berg and Läckgren in 1995, Dextranomer/hyalu ronic acid (DX/ HA), out of a number of injection sub stances 8) , is the most commonly used in VUR injection treatment in pediatrics and the only healing substance approved by the Food and Drug Administration for its safety.
There have been many reports on the early success rate of Deflux ® injection therapy and the overall success rate is relatively good, 6892% 6, 911) . In 2004, Kirsch report ed that the early success rates of Deflux ® injection using the hy drodistention implantation technique are similar to those of UNC 6) . In our study as well, the case that VUR was cured in an RNC test in the 3rd month after Deflux ® injection and reported a good success rate: the success rate was 84% in the first VCUG, but dropped slightly to 74% in the long term followup 17) . However, there is a problem in interpre ting these results, because longterm VCUG was only carried out for 45 ureters (13.4%) out of 334 treated ureters and there was a high dropout rate. On the other hand, unlike Läckgren's report, Lee and Gatti reported 18) rather disappointing longterm followup results in 2009. The success rate in the first postoperative VCUG was 73%, but recurrence was identified in 39 (26%) out of 150 ureters in the postoperative 1 year VCUG and the overall cumula tive failure rate was 54% (130/241 ureters). In our study, the success rate in the first RNC test conducted at 3 months after Deflux ® injection was 79.5% (333/419 ureters) and re latively good longterm followup results were shown with a success rate of 75.2% (212/282 ureters) at the 1 year follow up and 76.4% (97/127 ureters) at the 3 year followup. How ever, only 127 out of 419 ureters (30.3%) were tracked through the 3 years, which can be said to lack numeric significance. Previous studies have analyzed the factors that can pre dict the success rate of Deflux ® injection therapy. In the paper published in our center in 2007, the degree of VUR (P=0.035) and the presence or absence of voiding dysfunc tion (P=0.001) were the factors that could predict the success rate 12) . In 2013, Kajbafzadeh analyzed 372 pa tients who underwent Deflux ® injection therapy and the success rate was 86.6%. The degree of preoperative VUR, treatment techniques, and whether to form a mound, hyper/iso echogenic oval protuberance around the ure tero vesical junction in an ultrasound performed after the procedure were factors that can predict the success rate in the univa riate analysis. The degree of preoperative VUR and whether to form a mound were statistically signifi cantly related to the success rate in the multivariate analy sis 21) . In our study, the degree of preoperative VUR (P= 0.031) was a factor that can predict the success rate, but another predictor could be identified if more extensive research is performed.
There is no definite answer regarding how long follow up should be carried out after Deflux ® injection therapy.
According to a multicenter prospective trial that reported longterm followup results in recent years 19) , the early success rate was 68% (based on ureters, postoperative 6 months) in 284 patients (424 ureters). It was also reported that 46% of the entire patient group was followed up at postoperative 3 years and 21% of recurrence was identified between 6 months and 3 years in the ureters among them. Thus, the authors argued that even if successful injection therapy was conducted, the presence or absence of VUR needs to be tracked for at least 3 years. In this study, the re currence rate was 20.0% based on the ureters at post opera tive 3 years, showing a similar level of recurrence rate. Given that the presence or absence of VUR recur rence is not statistically correlated with postoperative febrile UTI occurrence in the reflux test carried out at postoperative 1 year, there is a need for longterm followup of at least 1 year or more after Deflux ® injection thera py. According to the longterm results of the endo scopic treatment of VUR with a bulking agent in a study publish ed by Stredele et al. in 2013, the success rate at 3 months after Deflux ® injection was 81.5% and the success rate after 37 months was 78.5%. Approximately 20% may experi ence recurrence at post operative 23 years, so a 3year followup was recommended after successful endoscopic treatment 22) . However, from the result that VUR was observed in 55.0% after 3 years of ureters that showed VUR in RNC test at 1 year, while VUR was ob served in 10.3% after 3 years of ureters without VUR at 1 year, we can draw conclusion that it is recommendable not to per orm followup RNC at 3 years routinely if no VUR at 1 year due to low recurrence rate of UTI though VUR per sists and high probability of no VUR at 3 years if no VUR at 1 year.
Previous studies have reported that the degree of VUR and the degree of voiding dysfunction influence the success rate of injection therapy 12) . This may be con sidered due to the fact that the position of Deflux ® uplift changes due to high detrusor pressure accom panying voiding dysfunction. According to the recent research of Puri et al. 20) , 47.3 % of patients with voiding dysfunction before surgery have been treated successfully. Our study did not identify a signifi cant correlation between the presence or absence of voiding dysfunction and the surgi cal success rate. When viewed in light of this information, future research seems to be needed to evaluate relation ship between voiding dys function and success rate.
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In this study, there were few cases of urinary tract infec tion due to VUR persisting after Deflux ® injection therapy (22.2%). Even if the statistical significance is insignificant due to the small number of patients, it can be assumed that the effect of Deflux ® injection therapy itself drops the pro bability of urinary tract infection. The study published by Baek et al. in 2013 explained that the pro bability of urinary tract infection after Deflux ® injection therapy drops be cause VUR grade decreases and bladder function is im proved, depending on the growth of the child 23) . This study has several limitations. The first includes the retrospective study characteristics, the somewhat small number of patients, and the large amount of RNC follow up loss (especially at 3 years) during the longterm follow up. The second limitation is that only the presence or ab sence of VUR was identified, and it was difficult to determine the grade due to the nature of the RNC test. The third limi tation is that the analysis of the longterm follow up results of Deflux ® injection therapy was evaluated by the presence or absence of postoperative VUR recur rence and the pre sence or absence of febrile UTI occur rence, while several other elements, including the degree of renal scarring and renal function etc., should also be considered. Finally, the number of patients who under went the DMSA scan and renal ultrasound for postope rative followup was so small that it was difficult to find out if there was a corre lation bet ween the size, shape, pa renchymal thickness of the kidney and the postoperative urinary tract infection. Thus, multi institutional prospec tive study will be needed to find an answer to the con troversy over the longterm followup results of Deflux ® injection therapy.
Conclusion
This study found that the success rates of Deflux ® injec tion therapy are excellent: 79.5% at postoperative 3 months, 75.2% at postoperative 1 year, and 76.4% at postoperative 3 years. The probability of urinary tract infec tion is not high, although VUR can occur after Deflux ® injection therapy, and if there is no VUR at postoperative 1 year, it is highly likely that there will be no VUR at post operative 3 years. Therefore, if there is no VUR at postope rative 1 year, it is recommendable that there is no need to follow up with RNC at 3 years. In the future, the longterm followup results of Deflux ® injection therapy through multiinstitu tional prospective research are needed.
